Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neurological function during long-term therapy with recombinant interferon alpha.

N Mayr1, J Zeitlhofer, L Deecke

  • 1Department of Neurology, University of Vienna, Austria.

The Journal of Neuropsychiatry and Clinical Neurosciences
|August 10, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.

Leukemia·2017
Same author

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Leukemia·2017
Same author

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Leukemia·2017
Same author

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Leukemia·2017
Same author

Response to Harrison et al. 'Clinically relevant differences between BCSH and WHO diagnostic criteria for ET'.

Leukemia·2016
Same author

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Leukemia·2016
Same journal

The Neuropsychiatric Phenotype of Klüver-Bucy Syndrome: A Systematic Review of Reported Cases.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same journal

Diffusion Tensor Imaging Correlates of Financial Capacity Instrument-Short Form Completion Time in Mild Cognitive Impairment.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same journal

A 3-Week Intensive Outpatient Program for Patients With Persistent Neuropsychiatric Symptoms After Remote TBI.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same journal

Outcomes of Integrated Practice Unit Treatment for Mild Traumatic Brain Injury and Co-occurring Conditions Among Veterans.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same journal

Case Study 12: A 57-Year-Old Man With Seizures, Paranoid Psychosis, and Catatonia.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same journal

Rates of Comorbid Psychiatric Conditions Among Adults With Hydrocephalus at a Hydrocephalus Specialty Center.

The Journal of neuropsychiatry and clinical neurosciences·2026
See all related articles

Recombinant human interferon alpha (rIFN) therapy in myeloproliferative disorders improved neurological and neuropsychological functions, including attention, memory, and muscle strength, without significant side effects.

Area of Science:

  • Neurology
  • Hematology
  • Pharmacology

Background:

  • Myeloproliferative disorders (MPDs) with thrombocytosis can lead to neurological complications.
  • Recombinant human interferon alpha (rIFN) is used to manage MPDs.

Purpose of the Study:

  • To evaluate the neurological and neuropsychological effects of rIFN therapy in patients with MPDs and thrombocytosis.
  • To assess the safety and efficacy of long-term rIFN treatment on neurological function.

Main Methods:

  • 14 patients with MPDs and thrombocytosis were monitored for neurological and neuropsychological function.
  • Assessments were conducted before and at 3, 6, 9, and 12 months during rIFN therapy (25 mU/week; range 10-35 mU/week).
  • Evaluated parameters included neurological examination, neuropsychological tests, visually evoked potentials (VEPs), and nerve conduction studies.

Related Experiment Videos

Main Results:

  • No significant overt neurological side effects were observed, with one possible unrelated cerebral insult.
  • Significant improvements were noted in attention, memory function, and tapping tests.
  • P2-N3 amplitudes of VEPs increased with platelet count normalization.
  • Muscular strength and compound muscle action potential amplitudes of median and peroneal nerves increased, inversely related to rIFN dose.

Conclusions:

  • Long-term, low to intermediate dose rIFN therapy in MPDs does not impair neurological function.
  • rIFN treatment is associated with enhanced muscle power and mental arousal levels.
  • rIFN appears to be a safe and potentially beneficial therapeutic option for neurological and physical well-being in MPD patients.